PAOG Stock Overview
PAO Group, Inc. se centra en tratamientos alternativos de atención al paciente.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PAO Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0013 |
| 52 Week High | US$0.0033 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -7.14% |
| 3 Month Change | 160.00% |
| 1 Year Change | 225.00% |
| 3 Year Change | -86.60% |
| 5 Year Change | -59.38% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PAOG | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -18.8% | -1.2% | -0.7% |
| 1Y | 225.0% | 15.8% | 25.9% |
Rentabilidad frente al sector: PAOG superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 20.4% el año pasado.
Rentabilidad vs. Mercado: PAOG superó al mercado US, que obtuvo un rendimiento del 20.5% el año pasado.
Price Volatility
| PAOG volatility | |
|---|---|
| PAOG Average Weekly Movement | 42.4% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: PAOGha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: PAOGha disminuido de 3431% a 45% en el último año, pero sigue siendo superior al 75% de los valores de US.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jim DiPrima | https://www.pao.group |
PAO Group, Inc. se centra en tratamientos alternativos de atención al paciente. La empresa, a través de sus filiales, se dedica al desarrollo, venta y distribución de productos de cannabis medicinal de primera calidad para el tratamiento de pacientes crónicos y terminales. La empresa tiene su sede en Sandusky, Ohio.
PAO Group, Inc. Fundamentals Summary
| PAOG fundamental statistics | |
|---|---|
| Market cap | US$2.29m |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs PAOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAOG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PAOG perform over the long term?
See historical performance and comparison